Jennifer Witcher

1.6k total citations
33 papers, 1.3k citations indexed

About

Jennifer Witcher is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Pharmacology. According to data from OpenAlex, Jennifer Witcher has authored 33 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Psychiatry and Mental health, 9 papers in Pediatrics, Perinatology and Child Health and 7 papers in Pharmacology. Recurrent topics in Jennifer Witcher's work include Attention Deficit Hyperactivity Disorder (10 papers), Pharmaceutical studies and practices (7 papers) and Pharmacogenetics and Drug Metabolism (6 papers). Jennifer Witcher is often cited by papers focused on Attention Deficit Hyperactivity Disorder (10 papers), Pharmaceutical studies and practices (7 papers) and Pharmacogenetics and Drug Metabolism (6 papers). Jennifer Witcher collaborates with scholars based in United States, United Kingdom and Japan. Jennifer Witcher's co-authors include John‐Michael Sauer, Barbara J. Ring, Amanda Long, Brian P. Smith, Holly R. Thomasson, K A DeSante, Holly A. Read, Joseph Biederman, David Michelson and James T. McCracken and has published in prestigious journals such as Scientific Reports, Antimicrobial Agents and Chemotherapy and Journal of the American Academy of Child & Adolescent Psychiatry.

In The Last Decade

Jennifer Witcher

31 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jennifer Witcher United States	17	693	307	252	234	212	33	1.3k
Massimo Carlo Mauri Italy	21	851 1.2×	372 1.2×	350 1.4×	116 0.5×	118 0.6×	60	1.5k
C. Barnas Austria	19	700 1.0×	197 0.6×	166 0.7×	91 0.4×	109 0.5×	61	1.2k
Manickam Aravagiri United States	23	1.0k 1.5×	272 0.9×	376 1.5×	73 0.3×	138 0.7×	50	1.8k
Wen‐Ho Chang Taiwan	22	1.1k 1.6×	231 0.8×	467 1.9×	100 0.4×	126 0.6×	37	1.8k
Judith C. Kando United States	15	741 1.1×	264 0.9×	99 0.4×	71 0.3×	199 0.9×	40	1.2k
Michael Paulzen Germany	20	594 0.9×	265 0.9×	128 0.5×	57 0.2×	255 1.2×	105	1.1k
Concetta D’Arrigo Italy	14	488 0.7×	196 0.6×	83 0.3×	109 0.5×	178 0.8×	15	843
Kristin L. Bigos United States	15	356 0.5×	256 0.8×	177 0.7×	218 0.9×	53 0.3×	26	1.1k
K. Otani Japan	18	432 0.6×	251 0.8×	279 1.1×	39 0.2×	160 0.8×	49	1.1k
C.M.E. Kremer United States	13	569 0.8×	651 2.1×	221 0.9×	106 0.5×	52 0.2×	34	1.2k

Countries citing papers authored by Jennifer Witcher

Since Specialization

Citations

This map shows the geographic impact of Jennifer Witcher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Witcher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Witcher more than expected).

Fields of papers citing papers by Jennifer Witcher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Witcher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Witcher. The network helps show where Jennifer Witcher may publish in the future.

Co-authorship network of co-authors of Jennifer Witcher

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Witcher. A scholar is included among the top collaborators of Jennifer Witcher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Witcher. Jennifer Witcher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Datta‐Mannan, Amita, Wen Xu, Kimberley Jackson, et al.. (2024). Evaluation of Pharmacokinetics of Lebrikizumab in Healthy Individuals After Subcutaneous Administration Using a Prefilled Syringe or Autoinjector in a Phase 1 Randomized Study. Clinical Therapeutics. 47(1). 55–61.

Pak, Y. Anne, Maria M. Posada, James A. Bacon, et al.. (2023). Prediction of the Renal Organic Anion Transporter 1 (OAT1)- Mediated Drug Interactions for LY404039, the Active Metabolite of Pomaglumetad Methionil. Pharmaceutical Research. 40(11). 2499–2511. 5 indexed citations

Byun, Joo‐Yun, Yi Ting Koh, Sun Young Jang, et al.. (2021). Target modulation and pharmacokinetics/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection. Scientific Reports. 11(1). 18671–18671. 7 indexed citations

Pak, Y. Anne, Amanda Long, Jennifer Witcher, et al.. (2016). In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1. Drug Metabolism and Disposition. 45(2). 137–144. 11 indexed citations

Nakano, Masako, et al.. (2016). Pharmacokinetic Profile and Palatability of Atomoxetine Oral Solution in Healthy Japanese Male Adults. Clinical Drug Investigation. 36(11). 903–911. 9 indexed citations

Naganawa, Mika, Gemma L. Dickinson, M. Zheng, et al.. (2015). Receptor Occupancy of the κ-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050. Journal of Pharmacology and Experimental Therapeutics. 356(2). 260–266. 49 indexed citations

Lowe, Stephen L., Conrad J. Wong, Jennifer Witcher, et al.. (2014). Safety, tolerability, and pharmacokinetic evaluation of single‐ and multiple‐ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects. The Journal of Clinical Pharmacology. 54(9). 968–978. 81 indexed citations

Nolin, Thomas D., George R. Aronoff, William H. Fissell, et al.. (2014). Pharmacokinetic Assessment in Patients Receiving Continuous RRT. Clinical Journal of the American Society of Nephrology. 10(1). 159–164. 35 indexed citations

Long, Amanda, Jennifer Witcher, Mary Pat Knadler, et al.. (2014). Relative Contributions of Presystemic and Systemic Peptidases to Oral Exposure of a Novel Metabotropic Glutamate 2/3 Receptor Agonist (LY404039) After Oral Administration of Prodrug Pomaglumetad Methionil (LY2140023). Journal of Pharmaceutical Sciences. 104(1). 207–214. 18 indexed citations

10.

Azuma, Junichi, Jennifer Witcher, Amanda Long, et al.. (2011). Pharmacokinetics, Safety, and Tolerability of Atomoxetine and Effect of CYP2D6*10/*10 Genotype in Healthy Japanese Men. The Journal of Clinical Pharmacology. 52(3). 388–403. 34 indexed citations

11.

Hazell, Philip, Katja Becker, Paula T. Trzepacz, et al.. (2009). Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. ADHD Attention Deficit and Hyperactivity Disorders. 1(2). 201–210. 23 indexed citations

12.

Trzepacz, Paula T., David W. Williams, Peter D. Feldman, et al.. (2007). CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. European Neuropsychopharmacology. 18(2). 79–86. 54 indexed citations

13.

Michelson, David, Holly A. Read, Dustin Ruff, et al.. (2007). CYP2D6 and Clinical Response to Atomoxetine in Children and Adolescents With ADHD. Journal of the American Academy of Child & Adolescent Psychiatry. 46(2). 242–251. 118 indexed citations

14.

Sauer, John‐Michael, Barbara J. Ring, & Jennifer Witcher. (2005). Clinical Pharmacokinetics of Atomoxetine. Clinical Pharmacokinetics. 44(6). 571–590. 180 indexed citations

15.

Sauer, John‐Michael, Amanda Long, Barbara J. Ring, et al.. (2004). Atomoxetine Hydrochloride: Clinical Drug-Drug Interaction Prediction and Outcome. Journal of Pharmacology and Experimental Therapeutics. 308(2). 410–418. 53 indexed citations

16.

Witcher, Jennifer, Amanda Long, Brian P. Smith, et al.. (2003). Atomoxetine Pharmacokinetics in Children and Adolescents with Attention Deficit Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology. 13(1). 53–63. 88 indexed citations

17.

Sauer, John‐Michael, G. Douglas Ponsler, Edward L. Mattiuz, et al.. (2003). Disposition and Metabolic Fate of Atomoxetine Hydrochloride: The Role of CYP2D6 in Human Disposition and Metabolism. Drug Metabolism and Disposition. 31(1). 98–107. 118 indexed citations

18.

Ernest, C. Steven, et al.. (2002). Effect of Potent CYP2D6 Inhibition by Paroxetine on Atomoxetine Pharmacokinetics. The Journal of Clinical Pharmacology. 42(11). 1219–1227. 79 indexed citations

19.

Spencer, Thomas, Joseph Biederman, John H. Heiligenstein, et al.. (2001). An Open-Label, Dose-Ranging Study of Atomoxetine in Children with Attention Deficit Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology. 11(3). 251–265. 120 indexed citations

20.

Witcher, Jennifer & F. Douglas Boudinot. (1996). Applications and Simulations of a Discontinuous Oral Absorption Pharmacokinetic Model. Pharmaceutical Research. 13(11). 1720–1724. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact